High Growth Tech Stocks In US With Potential For Expansion

The United States market is currently experiencing a mixed performance with major indexes such as the Dow Jones and S&P 500 showing modest gains, while the tech-heavy Nasdaq Composite has seen slight declines amid fluctuating trade policies and tariff exemptions. In this dynamic environment, identifying high growth tech stocks with potential for expansion requires careful consideration of factors such as innovation, market adaptability, and resilience to external economic pressures.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	20.44%	29.79%	★★★★★★
Arcutis Biotherapeutics	25.76%	58.17%	★★★★★★
TG Therapeutics	26.03%	37.60%	★★★★★★
Alkami Technology	20.46%	85.16%	★★★★★★
Travere Therapeutics	28.65%	65.75%	★★★★★★
Alnylam Pharmaceuticals	22.74%	58.77%	★★★★★★
TKO Group Holdings	22.48%	25.17%	★★★★★★
AVITA Medical	28.22%	55.77%	★★★★★★
Lumentum Holdings	21.61%	120.49%	★★★★★★
Ascendis Pharma	32.36%	59.79%	★★★★★★

Click here to see the full list of 232 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Alnylam Pharmaceuticals (NasdaqGS:ALNY)

Simply Wall St Growth Rating: ★★★★★★

Overview: Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing therapeutics based on ribonucleic acid interference with a market cap of approximately $30.78 billion.

Operations: Alnylam generates revenue primarily from the discovery, development, and commercialization of RNAi therapeutics, amounting to $2.25 billion. The company operates within the biotechnology sector with a focus on innovative therapeutic solutions.

Alnylam Pharmaceuticals has demonstrated a robust commitment to innovation, particularly through its recent FDA approval of AMVUTTRA for ATTR-CM and Qfitlia for hemophilia. These approvals not only enhance its product portfolio but also underscore its R&D capabilities, reflected in a significant 22.7% annual revenue growth. The company's strategic presentations at various healthcare conferences, coupled with the launch of groundbreaking RNAi therapeutics like vutrisiran, show a clear trajectory towards addressing critical unmet medical needs. Despite being unprofitable currently, Alnylam's projected earnings growth of 58.77% annually suggests potential for future profitability and leadership in the biotech sector.

• Navigate through the intricacies of Alnylam Pharmaceuticals with our comprehensive health report here.

• Examine Alnylam Pharmaceuticals' past performance report to understand how it has performed in the past.

Ascendis Pharma (NasdaqGS:ASND)

Simply Wall St Growth Rating: ★★★★★★

Overview: Ascendis Pharma A/S is a biopharmaceutical company specializing in the development of TransCon-based therapies for unmet medical needs across Denmark, Europe, North America, and globally, with a market cap of approximately $9.04 billion.

Operations: Ascendis Pharma generates revenue primarily from its biotechnology segment, amounting to €363.64 million. The company is focused on developing TransCon-based therapies to address unmet medical needs across various regions.

Ascendis Pharma is navigating a transformative phase with its recent NDA submission for TransCon CNP, targeting achondroplasia treatment, reflecting its commitment to addressing rare diseases through innovative drug development. Despite being unprofitable, the company's revenue is projected to grow at 32.4% annually, outpacing the US market average of 8.3%. With R&D expenses aligning closely with these ambitious projects, Ascendis also announced a share repurchase program valued at $18.25 million, signaling confidence in its future financial health. This strategic mix of product development and financial maneuvers positions Ascendis uniquely within the biotech landscape as it transitions towards profitability forecasted with an impressive annual earnings growth rate of 59.79%.

• Get an in-depth perspective on Ascendis Pharma's performance by reading our health report here.

• Explore historical data to track Ascendis Pharma's performance over time in our Past section.

Natera (NasdaqGS:NTRA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Natera, Inc. is a diagnostics company that offers molecular testing services globally, with a market cap of approximately $20.01 billion.

Operations: The company generates revenue primarily from the development and commercialization of molecular testing services, totaling approximately $1.70 billion.

Natera, a player in the genetic testing and diagnostics sector, is steering through a dynamic phase marked by strategic board expansions and intriguing clinical trials. With a revenue leap to $1.87 billion forecasted for 2025, the company's financial trajectory reflects vigorous growth, notably outpacing broader market trends. Recent R&D initiatives like the HEROES trial underscore Natera’s commitment to pioneering in oncological research, potentially reshaping therapeutic approaches in cancer care. Moreover, the adoption of its Signatera test for Medicare coverage marks a significant milestone, enhancing its standing in precision medicine and boosting its commercial prospects amidst competitive pressures.

• Unlock comprehensive insights into our analysis of Natera stock in this health report.

• Review our historical performance report to gain insights into Natera's's past performance.

Turning Ideas Into Actions

• Embark on your investment journey to our 232 US High Growth Tech and AI Stocks selection here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com